To evaluate the effects of the IL-18 peptide-based vaccines A and D in the amelioration of TNBS-induced colitis, mice were first immunized with vaccine, carrier or saline three-times to develop high levels of anti-IL-18 antibodies. The gene discussed is IL18; the disease is colitis.